Edition:
India

Immune Design Corp (IMDZ.OQ)

IMDZ.OQ on NASDAQ Stock Exchange Global Market

4.20USD
21 Nov 2017
Change (% chg)

$0.03 (+0.60%)
Prev Close
$4.18
Open
$4.15
Day's High
$4.30
Day's Low
$4.15
Volume
80,916
Avg. Vol
101,111
52-wk High
$13.00
52-wk Low
$3.80

Latest Key Developments (Source: Significant Developments)

Ecor1 Capital reports 7.4% passive stake in Immune Design
Tuesday, 7 Nov 2017 

Nov 6 (Reuters) - Ecor1 Capital Llc::Ecor1 Capital Llc reports 7.4% passive stake in Immune Design Corp as of Oct 25 - SEC filing‍​.  Full Article

Immune Design reports Q3 loss per share of $0.52
Thursday, 2 Nov 2017 

Nov 1 (Reuters) - Immune Design Corp -:IMMUNE DESIGN REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 LOSS PER SHARE $0.52.Q3 REVENUE $500,000.Q3 REVENUE VIEW $1.4 MILLION -- THOMSON REUTERS I/B/E/S.Q3 EARNINGS PER SHARE VIEW $-0.63 -- THOMSON REUTERS I/B/E/S.  Full Article

Immune Design prices offering of 19.5 million shares at $4.10 per share​
Wednesday, 25 Oct 2017 

Oct 24 (Reuters) - Immune Design Corp :Immune Design prices $80.0 million public offering of common stock.Says ‍priced public offering of 19.5 million shares of its common stock at price to public of $4.10 per share​.  Full Article

Immune Design proposes public offering of common stock
Tuesday, 24 Oct 2017 

Oct 23 (Reuters) - Immune Design Corp :Immune Design announces proposed public offering of common stock.Immune Design Corp - ‍plans to offer and sell up to 16 million shares of its common stock in an underwritten public offering​.Immune Design Corp - ‍net proceeds of offering to fund its Phase 3 clinical trial for CMB305 in synovial sarcoma patients & to continue to develop CA21.  Full Article

Immune Design gets positive FDA feedback on Phase 3 clinical trial design for CMB305
Tuesday, 17 Oct 2017 

Oct 16 (Reuters) - Immune Design Corp :Immune Design announces positive FDA feedback on Phase 3 clinical trial design for CMB305 in synovial sarcoma patients.Immune Design- plans to initiate pivotal Phase 3 trial to support a Biologics License Application (BLA) for CMB305 in patients with synovial sarcoma​.  Full Article

Bain Capital Public Equity Management LLC reports a 5.07 pct passive stake in Immune Design
Saturday, 7 Oct 2017 

Oct 6 (Reuters) - Immune Design Corp :Bain Capital Public Equity Management LLC reports a 5.07 percent passive stake in Immune Design Corp as of September 29, 2017 - SEC Filing‍​.  Full Article

Immune Design says it may offer shares of up to $50 mln
Tuesday, 4 Jul 2017 

July 3 (Reuters) - Immune Design Corp :Immune design corp - ‍immune design corp. Entered into a sales agreement with cowen and company, llc​.Immune design corp - ‍co may offer and sell shares of its common stock, par value $0.001 per share, having an aggregate offering price of up to $50 million​.Immune design corp - co may offer and sell, from time to time at its sole discretion through cowen, as its sales agent, shares of its common stock​.  Full Article

Immune Design Announces Advancement of First GLAAS-based Allergy Program into Clinical Development
Wednesday, 28 Sep 2016 

Immune Design Corp : Application of co's glaas discovery platform in Sanofi's phase 1 clinical trial evaluating a candidate for treatment of peanut allergy . Trial follows exclusive license agreement with co to discover, develop, commercialize products to treat a peanut allergy using GLAAS .Has received undisclosed milestone payment for start of trial, is eligible to receive future development,commercialization milestones.  Full Article

Victory Capital Management reports 6.23 pct passive stake in Immune Design - SEC filing
Friday, 23 Sep 2016 

Immune Design Corp :Victory Capital Management Inc reports 6.23 percent passive stake in Immune Design Corp as of July 31, 2016 - SEC filing.  Full Article

Immune Design Q2 loss per share $0.71
Wednesday, 10 Aug 2016 

Immune Design Corp : Immune design reports second quarter 2016 financial results and provides corporate update . Q2 revenue $1.1 million . Q2 earnings per share view $-0.68 -- Thomson Reuters I/B/E/S . Q2 loss per share $0.71 .Q2 revenue view $1.9 million -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Ecor1 Capital reports 7.4% passive stake in Immune Design

* Ecor1 Capital Llc reports 7.4% passive stake in Immune Design Corp as of Oct 25 - SEC filing‍​ Source text: (http://bit.ly/2zkI4Ki) Further company coverage: